Publication:
Real-life effect of a microcrystalline tyrosine adjuvanted mite immunotherapy in patients with allergic rhinitis.

Simple item page
dc.contributor.authorRoger, Albert
dc.contributor.authorMalet, Alfons
dc.contributor.authorMoreno, Victoria
dc.contributor.authorParra, Antonio
dc.contributor.authorGutiérrez, Diego
dc.contributor.authorLleonart, Ramón
dc.contributor.authorMoreno, Francisco
dc.contributor.authorValero, Antonio
dc.contributor.authorNavarro, Begoña
dc.contributor.authorHinojosa, Belén
dc.contributor.authorJusticia, José L
dc.date.accessioned2023-02-08T14:39:11Z
dc.date.available2023-02-08T14:39:11Z
dc.date.issued2020-01-08
dc.description.abstractAim: Evaluate the effectiveness and safety of immunotherapy with Acarovac Plus® in a 1-year prospective multicentered real-life study. Methods: A total of 118 adults with allergic rhinitis sensitized to Dermatophagoides received subcutaneous immunotherapy with Acarovac Plus. Treatment outcomes were evaluated at baseline, 6 months and 1 year after treatment initiation. Primary end point was the evolution of the combined symptom and medication score. Secondary end points included other effectiveness outcomes and measurement of product tolerability. Results: Acarovac Plus induced significant improvements in primary and secondary end points after 6 months compared with baseline. These differences persisted after 1 year of treatment (p
dc.identifier.doi10.2217/imt-2019-0205
dc.identifier.essn1750-7448
dc.identifier.pmid31910695
dc.identifier.unpaywallURLhttps://www.futuremedicine.com/doi/pdf/10.2217/imt-2019-0205
dc.identifier.urihttp://hdl.handle.net/10668/14927
dc.issue.number1
dc.journal.titleImmunotherapy
dc.journal.titleabbreviationImmunotherapy
dc.language.isoen
dc.organizationHospital Universitario Juan Ramón Jiménez
dc.page.number53-62
dc.pubmedtypeJournal Article
dc.pubmedtypeMulticenter Study
dc.pubmedtypeObservational Study
dc.pubmedtypeResearch Support, Non-U.S. Gov't
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International
dc.rights.accessRightsopen access
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.subjectDermatophagoides pteronyssinus
dc.subjectadjuvants
dc.subjectallergic rhinitis
dc.subjecteffectiveness
dc.subjecthouse dust mites
dc.subjectreal-life clinical practice
dc.subjectsafety
dc.subjectsubcutaneous allergen immunotherapy
dc.subject.meshAdjuvants, Immunologic
dc.subject.meshAdolescent
dc.subject.meshAdult
dc.subject.meshAged
dc.subject.meshAnimals
dc.subject.meshAntigens, Dermatophagoides
dc.subject.meshDesensitization, Immunologic
dc.subject.meshFemale
dc.subject.meshHumans
dc.subject.meshInjections, Subcutaneous
dc.subject.meshMale
dc.subject.meshMiddle Aged
dc.subject.meshNovobiocin
dc.subject.meshProspective Studies
dc.subject.meshPyroglyphidae
dc.subject.meshRhinitis, Allergic
dc.subject.meshTreatment Outcome
dc.subject.meshTyrosine
dc.subject.meshYoung Adult
dc.titleReal-life effect of a microcrystalline tyrosine adjuvanted mite immunotherapy in patients with allergic rhinitis.
dc.typeresearch article
dc.type.hasVersionVoR
dc.volume.number12
dspace.entity.typePublication

Files

Collections

SAS - Hospital Universitario Juan Ramón Jiménez

© 2023 – Repositorio Institucional de Salud de Andalucía - Fundación Pública Andaluza Progreso y Salud - Consejería de Salud y Consumo de la Junta de Andalucía